The Most Common Curable STI
Trichomonas vaginalis (TV) is the most common curable STI in the United states.1 Over 3.7 million people in the United States have TV, which is a higher prevalence than chlamydia and gonorrhea infections combined.1 The CDC recommends testing women for TV infection if they are symptomatic or at increased risk of infection.2 The CDC and ACOG also recommend the use of a highly sensitive and specific test, such as the Aptima® Trichomonas vaginalis assay.2,3
Detect Up To 100% of TV Infections
The Aptima Trichomonas vaginalis assay is an rRNA-based NAAT that provides up to 100% sensitivity in detecting TV for both symptomatic and asymptomatic patients.4 This assay overcomes challenges associated with traditional, less sensitive methodologies because it can detect a fraction of one organism, whereas wet mount requires at least 10,000 motile organisms/mL to visualize.4,5
References:
1. CDC. CDC Fact Sheet: Incidence, Prevalence and Cost of Sexually Transmitted Infections in the United States. https://www.cdc.gov/std/stats/sti-estimates-fact-sheet-feb-2013.pdf. February 2013. 2. Workowski, et al. Sexually Transmitted Infections Treatment Guidelines 2021. MMWR Recomm Rep 2021;70(4):1-187.doi.org/10.15585/mmwr.rr7004a1. 3. ACOG Practice Bulletin. Vaginitis in Nonpregnant Patients. Washington; DC: American College of Obstetricians and Gynecologists; 2020:135:e1-17. No. 215. 4. Aptima Trichomonas vaginalis Assay. US package insert 503684. Hologic, Inc., 2020. 5. Garber GE. The laboratory diagnosis of Trichomonas vaginalis. Can J Infect Dis Med Microbiol. 2005; 16(1):35-38. doi.org/10.1155/2005/373920
Related Products
Identify a Common Viral Threat
Globally, over 4.1 billion people are infected with HSV-1 and HSV-2 and the signs and symptoms can overlap.1 It is only through laboratory tests that these subtypes can be differentiated, which is important for managing herpes infections and identifying the risk of transmission to neonates and among sex partners.2,3
The Accurate Testing Needed For Proper Treatment
NAATs, such as the Aptima® HSV 1 & 2 assay, are recommended by the CDC and WHO for HSV diagnosis. They are increasingly preferred over viral culture to diagnose genital herpes due to higher sensitivity, ease of specimen collection and transportation and faster results.2,3 The Aptima HSV 1 & 2 assay distinguishes between HSV-1 and HSV-2 with significant reduction in hands-on time for laboratory professionals when compared to culture and other instrument platforms.4-6
References
1. WHO. Herpes simplex virus. World Health Organization. Last reviewed May 1, 2020. Accessed. September 10, 2021. https://www.who.int/news-room/fact-sheets/detail/herpes-simplex-virus. 2. WHO. WHO guidelines For The Treatment of Genital Herpes Simplex Virus. World Health Organization. Last reviewed March 11, 2016. Accessed September 10, 2021. https://www.who.int/publications/i/item/978924154987 3. Workowski, et al. Sexually Transmitted Infections Treatment Guidelines 2021. MMWR Recomm Rep 2021;70. 4. Aptima HSV 1 & 2 assay. US package insert AW-15346-001. Hologic, Inc., 2019. 5. LeGoff J, et al. Diagnosis of genital herpes simplex virus infection in the clinical laboratory. Virol J. 2014;11:83. doi:10.1186/1743-422X-11-83. 6. A. Jassem, Comparative Evaluation of the Aptima HSV 1&2 Assay and a Lab Developed Real-time PCR Test for Detection of HSV-1 and HSV-2 Viruses, presented at ESCV 2016 Poster No. PP20.
Related Products